Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 13 European countries. In 2023, Teva saved the healthcare systems more than 2.9 billion EUR across 13 European countries in which we support more than 120,000 jobs.
TPE
Teva Pharmaceuticals Europe
Company · ISR · EU Transparency Register 27116427434-57
2
positions filed
in the 326 files tracked
2
legislative files
of 326 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #503 by legislative files engaged — a count of participation, not a measure of influence.
2
declared lobbying FTE
self-declared
€600K+
declared costs / yr (floor)
3
EP accreditations
as declared to the register
2011
in the register since
Declares membership of
- Medicines for Europe - https://www.medicinesforeurope.com/
- EFPIA - https://www.efpia.eu/about-us/membership/
- Within CEFIC :
- > EFCG (European Fine Chemicals Group - a CEFIC group) - https://efcg.cefic.org/
- > APIC (Active Pharmaceuticals Ingredients Committee) - https://www.apic.cefic.org/
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- Teva Pharmaceuticals Europe BV (Teva)
- Head office
- Haarlem, Netherlands
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Teva in PolicySpeak: request access →
Work at Teva Pharmaceuticals Europe? so we know who speaks for it.
Their record over time
Teva Pharmaceuticals Europe filed 2 positions between 7 Mar 2025 and 26 Jan 2026, across 2 of the 326 legislative files tracked here, attaching a full position paper 1 time.
2025 · 1 filed2026 · 1 filed
What they argued
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 13 European countries. In 2024, Teva saved healthcare systems over 2.9billion and supported more than 100,000 jobs. A significant share of our portfolio, especially offpatent medicines, is procured through public tenders.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- Cefic · 2 files in common
- EDF - Electricité de France · 2 files in common
- DIGITALEUROPE · 2 files in common
- Danish Chamber of Commerce · 2 files in common
- FEAD - European Waste Management Association · 2 files in common
Showing 5 of 128.
Is this your organization?
Everything on this page comes from Teva Pharmaceuticals Europe’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.